Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Adverse drug reactions and debrisoquine/sparteine (P450IID6) polymorphism in patients with fibromyalgia.

Clinical rheumatology - 1 May 1997

Skeith K J, Hussain M S, Coutts R T, Ramos-Remus C, Avina-Zubieta J A, Russell A S

Abstract excerpt

OBJECTIVE: To assess the frequency of adverse drug reaction in patients with fibromyalgia in relation to medications prescribed for this condition. To evaluate the potential role of the P450IID6 phenotype in the pathogenesis of these adverse drug reactions. METHODS: Thirty-five patients with fibromyalgia were assessed using a structured questionnaire with demographic and clinical data and perceived adverse drug...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Analysis of Variance
Share to Arthritis, Rheumatoid

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Canada

Share to Cytochrome P-450 CYP2D6

Share to Debrisoquin

Share to Phenotype

Share to Polymorphism, Genetic

Share to Prevalence

Source

Identifiers

PMID: 9184268
DOI: 10.1007/BF02238966

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Adverse drug reactions and debrisoquine/sparteine (P450IID6) polymorphism in patients with fibromyalgia.PMID 9184268Read ↗

Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.Semantic proximity Read ↗

No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline.Semantic proximity Read ↗

Potent inhibition of cytochrome P450IID6 (debrisoquin 4-hydroxylase) by flecainide in vitro and in vivo.Semantic proximity Read ↗

Debrisoquine hydroxylation phenotypes of patients with high versus low to normal serum antidepressant concentrations.Semantic proximity Read ↗

Phenotype/genotype relationships for the cytochrome P450 enzyme CYP2D6 in rheumatoid arthritis: influence of drug therapy and disease activity.Semantic proximity Read ↗

CYP 2D6 PM phenotype hypothesis of antidepressant extrapyramidal side-effects.Semantic proximity Read ↗

Adverse drug reaction reporting and retrospective phenotyping for oxidation polymorphism.Semantic proximity Read ↗

The influence of the sparteine/debrisoquine genetic polymorphism on the disposition of dexfenfluramine.Semantic proximity Read ↗

Are poor metabolisers of sparteine/debrisoquine less pain tolerant than extensive metabolisers?Semantic proximity Read ↗

Comparative effects of the diastereoisomers, quinine and quinidine in producing phenocopy debrisoquine poor metabolisers (PMs) in healthy volunteers.Semantic proximity Read ↗

3,4-Dehydrodebrisoquine, a novel debrisoquine metabolite formed from 4-hydroxydebrisoquine that affects the CYP2D6 metabolic ratio.Semantic proximity Read ↗

Venlafaxine serum levels and CYP2D6 genotype.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.